Never Give Up: Amarin Will Appeal Latest Vascepa Patent Loss
Company Still Sees Profit Potential Even With US Generic Competitors
A Federal Circuit panel affirmed a district court decision in favor of two generics makers, but Amarin will seek a hearing from the full 12-member appellate court. Vascepa marketing is unchanged for now.
You may also be interested in...
The European Medicines Agency has recommended in favor of approval for Amarin’s fish-oil derivative, Vazkepa.
With an approval nod from the EMA’s scientific committee for its fish oil product Vazkepa, launch plans for the EU for this “multi-billion dollar” opportunity are on track, says Amarin CEO.
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.